DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 22334/S-22
NDA 203985/S-3

SUPPLEMENT APPROVAL

Novartis Pharmaceuticals Corp.
Attention: Lincy Thomas, PharmD, MBA
Director, Drug Regulatory Affairs
One Health Plaza
East Hanover, NJ 07936

Dear Dr. Thomas:

Please refer to your Supplemental New Drug Application (sNDA) dated May 31, 2013, received May 31, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for AFINITOR (everolimus) tablets for oral administration; 2.5 mg, 5 mg, 7.5 mg and 10 mg.

Please also refer to your Supplemental New Drug Application (sNDA) dated June 18, 2013, received June 18, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for AFINITOR DISPERZ (everolimus tablets for oral suspension); 2 mg, 3 mg, and 5 mg.

We acknowledge receipt of your amendments to NDA 22334/S-22 dated September 20, October 15, October 18, and October 29, 2013. We also acknowledge receipt of your amendments to NDA 203985/S-3 dated September 23, October 14, October 18, and October 29, 2013. We also refer to your submission of October 17, 2012, containing a postmarketing requirement (PMR) final study report for Study CRAD001C2325 and to our October 12, 2013, letter stating that PMR 1756-2 had been fulfilled.

These Prior Approval" supplemental new drug applications provide for modifications of the INDICATIONS AND USAGE, subsection 1.2 [Advanced Neuroendocrine Tumors of Pancreatic Origin (PNET)] and the Patient Package Insert to state that AFINITOR is not indicated for the treatment of patients with functional carcinoid tumors and for modifications to the CLINICAL STUDIES, Advanced Neuroendocrine Tumors subsection (14.2) to include the results of the final analysis of overall survival from Study CRAD001C2325.

APPROVAL & LABELING

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

WAIVER OF HIGHLIGHTS SECTION

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling text for the package insert and patient package insert, with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory

comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/opacom/morechoices/fdaforms/cder.html; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Ms. Sharon Sickafuse, Senior Regulatory Health Project Manager, at (301) 796-2320.

Sincerely,

{See appended electronic signature page}

Patricia Keegan, M.D.
Director
Division of Oncology Products 2
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

PATRICIA KEEGAN
11/06/2013